Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px

Document › Details

GenSight Biologics S.A.. (10/22/20). "Press Release: GenSight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With US and European Institutional Investors". Paris.

	Organisation	GenSight Biologics S.A. (Euronext: SIGHT)
	Organisation 2	Arix Bioscience plc (LSE: ARIX)
	Today	Arix Bioscience (Group)
	Group	Arix Bioscience (Group)
	Product	Lumevoq®
	Product 2	investment banking
	Index term	GenSight Biologics–SEVERAL: investment, 202010 private placement €25m led by Arix Bioscience + Invus + Sofinnova Partners
	Person	Gilly, Bernard (GenSight Biologics 201304 CEO + Co-founder before Fovea + Sofinnova Partners + Transgene)
	Person 2	Gidoin, Thomas (GenSight Biologics 201507 CFO)

Original document
accessed by [iito] on 2020-10-23

Record changed: 2020-12-09

Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for GenSight Biologics S.A. (Euronext: SIGHT)

[1] GenSight Biologics S.A.. (4/3/18). "Press Release: GenSight Biologics Announces Topline Results from REVERSE Phase III Clinical Trial of GS010 in Patients with Leber Hereditary Optic Neuropathy (LHON)". Paris....
[2] GenSight Biologics S.A.. (8/1/17). "Press Relase: GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy". Paris....
[3] GenSight Biologics S.A.. (7/28/17). "Press Relase: GenSight Biologics Reports Interim Financial Results for the First Half of 2017". Paris....
[4] GenSight Biologics S.A.. (6/23/17). "Press Release: GenSight Biologics Successfully Raises €22.5 Million from Leading Investors in the US and Europe [Not for distribution in Canada, Australia and Japan]". Paris....
[5] Reuters. (6/23/17). "News: BRIEF – Gensight Biologics Raises 22.5 Million Euros"....
[6] Euronext N.V.. (7/13/16). "Press Release: GenSight Biologics Lists on Euronext to Become Europe's First Listed Gene Therapy Company. €40 Million Raised, Market Capitalisation €149 Million". Paris....
[7] GenSight Biologics S.A.. (7/23/15). "Press Release: GenSight Biologics Closes $36 Million Series B Preferred Stock Financing". Paris....
[8] Abingworth LLP. (2/28/14). "Press Release: Abingworth Raises £225m ($375m) in Its Tenth Life Sciences Fund". London....
[9] GenSight Biologics S.A.. (4/8/13). "Press Release: GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]